Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

Employee Rating

3.9More
TypePublic
HQCambridge, US
Founded2008
Size (employees)382 (est)
Websiteagios.com
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, (HQ)
88 Sidney St
Show all (1)
Report incorrect company information

Agios Pharmaceuticals Financials and Metrics

Agios Pharmaceuticals Revenue

Agios Pharmaceuticals's revenue was reported to be $43.01 m in FY, 2017
USD

Revenue (Q3, 2018)

15.2m

Gross profit (Q3, 2018)

14.5m

Gross profit margin (Q3, 2018), %

95.4%

Net income (Q3, 2018)

(94.7m)

EBIT (Q3, 2018)

(99.2m)

Market capitalization (4-Dec-2018)

3.1b

Closing stock price (4-Dec-2018)

54.1

Cash (30-Sep-2018)

156.5m
Agios Pharmaceuticals's current market capitalization is $3.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.5m65.4m59.1m69.9m43.0m

Revenue growth, %

156%(10%)18%

General and administrative expense

9.9m36.0m50.7m71.1m

R&D expense

54.5m141.8m220.2m292.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

6.3m8.4m34.2m13.2m5.5m31.3m7.0m9.0m10.5m11.4m8.8m49.2m15.2m

Cost of goods sold

695.0k

Gross profit

14.5m

Gross profit Margin, %

95%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6m14.0m71.8m160.8m102.7m

Accounts Receivable

2.3m600.0k

Inventories

2.5m4.8m8.7m10.3m

Current Assets

169.7m359.5m337.3m559.9m445.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

106.0m32.8m108.2m70.0m35.3m72.5m80.0m39.0m234.0m285.5m200.3m138.7m132.7m364.5m210.3m156.5m

Accounts Receivable

2.6m

Inventories

863.0k

Current Assets

198.8m172.4m245.2m247.6m364.1m390.2m371.7m329.5m484.2m600.9m506.9m604.7m528.3m803.0m753.8m695.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.4m)(53.5m)(117.7m)(198.5m)(314.7m)

Depreciation and Amortization

1.4m1.4m3.3m5.7m6.4m

Inventories

Accounts Payable

30.0k7.6m4.2m3.5m5.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(11.2m)(12.2m)(18.3m)(26.8m)(5.0m)(36.9m)(77.1m)(23.2m)(79.2m)(142.0m)(66.2m)(149.2m)(226.4m)(90.8m)(159.6m)(254.2m)

Depreciation and Amortization

332.0k1.0m1.2m2.2m1.2m2.6m4.0m1.6m3.2m4.8m1.7m3.5m5.3m

Inventories

(863.0k)

Accounts Payable

720.0k5.4m2.4m12.6m(1.2m)(1.3m)(293.0k)3.8m1.7m(994.0k)4.9m742.0k(4.5m)(6.2m)(5.8m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Agios Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Agios Pharmaceuticals News and Updates

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.
Report incorrect company information

Agios Pharmaceuticals Blogs

Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma Content Import Fri, 11/16/2018 - 07:02 Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma…

Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting

Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting Content Import Thu, 11/01/2018 - 09:22 Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting Nov 1, 2018 This release is a backfill from a News Wire General …

Q3 2018 Agios Pharmaceuticals Inc Earnings Conference Call

Q3 2018 Agios Pharmaceuticals Inc Earnings Conference Call william.meady@… Thu, 10/18/2018 - 07:20 Q3 2018 Agios Pharmaceuticals Inc Earnings Conference Call Display "add to calendar" false Event Type Earnings Conference Call …

Andrew Berens, M.D.

Andrew Berens, M.D. James.Jordan@n… Wed, 09/26/2018 - 09:27 Andrew Berens M.D. Leerink Partners

Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018

CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 2, 2018 at 8:00

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- - Approval of TIBSOVO ® was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission (CR) and CR with Partial Hematologic Recovery (CRh) and Rate of Conversion to Transfusion Independence 1 - TIBSOVO 250 mg bottle TIBSOVO

Agios Pharmaceuticals Company Life and Culture

Report incorrect company information

Agios Pharmaceuticals Frequently Asked Questions

  • When was Agios Pharmaceuticals founded?

    Agios Pharmaceuticals was founded in 2008.

  • How many employees does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 382 employees.

  • What is Agios Pharmaceuticals revenue?

    Latest Agios Pharmaceuticals annual revenue is $43 m.

  • What is Agios Pharmaceuticals revenue per employee?

    Latest Agios Pharmaceuticals revenue per employee is $112.6 k.

  • Who are Agios Pharmaceuticals competitors?

    Competitors of Agios Pharmaceuticals include Varex Imaging, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is Agios Pharmaceuticals headquarters?

    Agios Pharmaceuticals headquarters is located at 88 Sidney St, Cambridge.

  • Where are Agios Pharmaceuticals offices?

    Agios Pharmaceuticals has an office in Cambridge.

  • How many offices does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 1 office.